Please choose your application, enter the information requested below. * Marked fields are mandatory.
Product Description
The Jurkat cells were treated with Fas Antibody and isolated by limiting dilution to obtain a cell line that had a low spontaneous rate of resistance to Fas-medicated apoptosis. The resulting wild-type A3 subclone is very sensitive to Fas-mediated apoptosis. Wild-type A3 cells were made neomycin resistant and treated with three cycles of exposure to the frameshifting mutagen ICR-191 to isolate clones harboring recessive mutations that were resistant to killing by Fas antibody. ICR-191 treated clones were serially diluted in 96-well plates in the presence of Fas Antibody for 3 to 5 weeks. Two of these ICR-191 treated clones have been deposited at the ATCC. They are I 9. 2, a clone with a mutation in the cysteine protease caspase-8/FLICE and I 2. 1, a clone with a mutation in the adaptor FADD.
SubculturingCultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2×10^5 viable cells/ml. Maintain cell density between 1×10^5 and 1×10^6 viable cells/ml.
related data
Get valuable resources and offers directly to your email.
